Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma

por Nairismägi, M. -L., Gerritsen, M. E., Li, Z. M., Wijaya, G. C., Chia, B. K. H., Laurensia, Y., Lim, J. Q., Yeoh, K. W., Yao, X. S., Pang, W. L., Bisconte, A., Hill, R. J., Bradshaw, J. M., Huang, D., Song, T. L. L., Ng, C. C. Y., Rajasegaran, V., Tang, T., Tang, Q. Q., Xia, X. J., Kang, T. B., Teh, B. T., Lim, S. T., Ong, C. K., Tan, J.
Publicado 2018

JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma

por Nairismägi, M-L, Tan, J, Lim, J Q, Nagarajan, S, Ng, C C Y, Rajasegaran, V, Huang, D, Lim, W K, Laurensia, Y, Wijaya, G C, Li, Z M, Cutcutache, I, Pang, W L, Thangaraju, S, Ha, J, Khoo, L P, Chin, S T, Dey, S, Poore, G, Tan, L H C, Koh, H K M, Sabai, K, Rao, H-L, Chuah, K L, Ho, Y-H, Ng, S-B, Chuang, S-S, Zhang, F, Liu, Y-H, Pongpruttipan, T, Ko, Y H, Cheah, P-L, Karim, N, Chng, W-J, Tang, T, Tao, M, Tay, K, Farid, M, Quek, R, Rozen, S G, Tan, P, Teh, B T, Lim, S T, Tan, S-Y, Ong, C K
Publicado 2016